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TheHippokinasepathwayis emergingasaconservedsignaling pathway thatis essential fororgan growth andtumorigenesis in
Drosophila and mammalians. Although the signaling of the core kinases is relatively well understood, less is known about
the upstream inputs, downstream outputs and regulation of the whole cascade. Enrichment of the Hippo pathway components
with WW domains and their cognate proline-rich interacting motifs provides a versatile platform for further understanding
the mechanisms that regulate organ growth and tumorigenesis. Here, we review recently discovered mechanisms of WW
domain-mediated interactions that contribute to the regulation of the Hippo signaling pathway in tumorigenesis. We further
discuss new insights and future directions on the emerging role of such regulation.
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Themechanismscontrolling mammalian organ size have been
the interest of scientists for a long time. During the last few
years, immense progress has been made in deciphering these
mechanisms and their implications in disease development,
including cancer. The regulation of organ growth is controlled
by the number of cell divisionsandthe rateofcelldeath.These
processes regulate tissue homeostasis and maintain the
proper function of organs. The recent discovery of the Hippo
pathway as a key regulator of organ growth in fruit ﬂies has
generated deeper insightsintothe mechanism oforgan size.
1,2
Moreover, deregulation of the Hippo pathway components in
many different types of cancers furthers its critical role in
tumorigenesis (reviewed in Zhao et al.
3). Although signiﬁcant
progress has been made in understanding the core signaling
cascadeoftheHippopathway,muchlesshasbeenachievedin
exploring the regulation of the pathway. Recently, much
attention was given to the unusual abundance of WW modules
and their interacting cognates within signaling molecules of the
Hippo pathway.
4,5 This prevalence of WW domain-mediated
complexes in the Hippo pathway perhaps facilitates its
molecular analysis, aids in prediction of new pathway
components and uncovers new mechanisms of regulation.
WW Domains
Many of the signaling proteins contain modular domains that
facilitate protein-protein interactions, often through the
recognition of speciﬁc and short peptide motifs in their binding
partners. These interactions are mostly regulated by post-
translational modiﬁcations, for example, phosphorylation.
Speciﬁc protein-protein interactions can thereby control the
subcellular localization, enzymatic activity and the assembly
of multi-protein complexes, thus allowing the ﬂow of informa-
tion through signaling pathways. One such example is the
WW domain modules’ interactions.
WW domain, the smallest module that naturally occurs,
consists of B35–40 amino acid residues, including two highly
conserved tryptophan (W) residues separated by 20–23
amino acids in the polypeptide chain.
6–8 These two W amino
acids give the domain its name, WW domain. Originally, WW
domains were identiﬁed through detailed characterization of
the Yes-associated protein (YAP) based on computer-aided
analysis of imperfectly repeated sequences in the mouse
isoform of YAP, and in yeast factor RSP5.
7,8 Functional
screen of a cDNA expression library identiﬁed the ﬁrst two
putative WW domain ligands, WBP1 and 2.
9,10 To date, WW
domains constitute ﬁve classes depending on the content of
theircognateproline-richbindingmotifs(PRM).
11–14Themost
abundant type of WW domains are class-I WW domains,
which bind to PPxY motifs, where P is proline, x is any amino
acid and Y is tyrosine. Although WW domains within different
proteins might have a very similar structure, they have
differential binding to various ligands. Moreover, different
WW domains falling in a tandemrepeat manner have different
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www.nature.com/cddisbinding properties to different proteins, suggesting that WW
domains bind to a vast repertoire of different proteins and
that they might be part of complexes bridging blocks.
15–17
WW domain-containing proteins appear to be very
important in homeostasis as they occur in proteins involved
in a wide array of biological processes including transcription,
apoptosis, differentiation, splicing and ubiquitination. In fact,
these domainsgained their essential role after being shown to
be involved in human diseases including, Liddle’s syndrome
of hypertension, where the WW domain ligand (PPxY
domain) is deleted or mutated,
18,19 muscular dystrophy,
20,21
Alzheimer’s,
22–24 Huntington’s diseases,
25,26 Golabi-Ito-Hall
syndrome of mental retardation, in which the binding of
Y65C-mutated WW domain of polyglutamine tract-binding
protein 1 (PQBP1) to its cognate proline-rich ligands is
abrogated,
27 and more recently cancer.
3,28–30 Moreover,
WW domain-containing proteins have gained further interest
after being identiﬁed in the Hippo tumor suppressor pathway.
Hippo Tumor Suppressor Pathway
The fact that separate WW domains from the same protein,
or closely related proteins, can have different speciﬁcities for
proteinligands,andthatasinglepolypeptidecanbindmultiple
classes of WW domains through separate PRM suggested
thatWWdomainsprovidea versatileplatformtolinkindividual
proteins into physiologically important networks.
16,17 One
such important network that has received much attention in
the last few years is the Hippo tumor suppressor pathway.
The Hippo pathway is a highly conserved pathway that
regulates tissue growth and organ size by regulating
cell growth, proliferation, differentiation and apoptosis.
3,29
Inactivation or mutations of some components of the pathway
were identiﬁed in different types of cancer.
3,29,31 The Hippo
pathway is composed of a kinase cascade core that includes
MST1/2 serine/threonine kinase (ortholog of Hpo), WW45
scaffold protein (Sav), MOB (Mts) and LATS1/2 kinases (Wts)
(Figure 1). This kinase cascade is activated by a mechanism
that is not yet fully established, although some proteins were
identiﬁed to feed into the core Hippo kinase cassette-like Fat,
Dachsous (Dchs), Kibra, Expanded (Ex), Merlin (Mer) and
others (reviewed in Grusche et al.
32). Activation of the core
cascade leads to phosphorylation of YAP
33–35 and TAZ
36
(Yki in ﬂies) leading to their sequestration in the cytoplasm,
preventing their translocation to the nucleus and binding to
TEAD transcription factor, thereby inhibiting transcription
of downstream target genes implicated in proliferation, anti-
apoptosis and epithelial-to-mesenchymal transition (EMT).
37
A unique feature of the Hippo pathway is the high
prevalence of WW domain-mediated complexes, deﬁned
recently as WW modularity of the Hippo pathway.
4 The WW
domain containing proteins occur at different levels of the
Hippo pathway. In the core components of the Hippo pathway
in both Drosophila and mammals, the interactions are
mediated via PPxY motifs and WW domains. In Drosophila,
Hpo and Wts each contain PPxY motifs, and Sav contains two
WW domains. In mammals, the core cassette also contains
either PPxY/F motifs (Table 1), as in the case of LATS1/2 and
MST1/2, or WW domains, as in case of WW45.
4 In addition,
the nuclear effectors of the pathway, Yki in ﬂies and YAP or
TAZ in mammals, function through WW–PPxY interaction.
Indeed, it has also been shown that the WW domains of YAP
are crucial for YAP transcriptional co-activation function
+
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Figure 1 ITCH regulates the Hippo pathway by degrading LATS1. The E3
ubiquitin ligase ITCH interacts with LATS1 by WW domain–PPxY motif-dependent
manner leading to ubiquitination and protaesomal degradation of LATS1. This
results in reduced YAPS127 phosphorylation, thus less cytoplasmic sequestration
by binding to 14-3-3 protein, reduced YAP protaesomal degradation mediated by
b-TRCP E3 ligase and consequently enhanced YAP translocation to the nucleus to
mediate YAP dependent co-activation of TEAD-responsive genes, including those
implicated in proliferation, anti-apoptosis and EMT. Upon activation of the pathway,
ITCH–LATS1 interaction is enhanced leading to more efﬁcient degradation of
LATS1 attenuating its phosphorylation activity of YAP. This functional association
might have a role in ﬁne-tuning the outcome of the Hippo pathway and could
be deregulated in speciﬁc setting such as in tumorigenesis.
Table 1 Examples of WW domain and PPxY-containing proteins in the
Hippo pathway
WW Domain proteins
YAP1/2 1-WW and 2-WW
3,33–35,37,46
TAZ 1-WW
29,36,59
KIBRA 2-WW
38–40
WW45 (SAV1) 2-WW
60,61
ITCH 4-WW
42,43
PPXY/F-containing proteins
DCHS1/2 4-PPxF and 2-PPxF
a 4,32,62
FT1/2 PPxY and PPxF
a 4,63–65
CRB1/2 1-PPxY and 2-PPxF
a 4,66,67
MST1/2 1-PPxF and 1-PPxF
a 4,60,68,69
LATS1/2 2-PPxY and 1-PPxY
34,35
WBP2 3-PPxY
47,48
AMOT 2-PPxY
49,51
AMOTL1/2 2-PPxY
50
ASPP1/2 1-PPxY and 1-PPxF
a 4,52,53,70
P73 1-PPxY
28,30,44,45
ERBB4 3-PPxY
28,30,71–73
SMAD1 1-PPxY
74
RUNX2 1-PPxY
28,30,59,75
DVL2 1-PPxY
76
aPPxF motif was suggested by Sudol and Harvey
4 as a potential WW domain
ligand based on in vitro results.
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37 Not only do the core
components or the downstream effectors contain WW
domains but also several upstream regulators of the Hippo
pathway, in both Drosophila and mammals, contain
either WW or PPxY motifs. For example, the WW domain
protein Kibra is a Hippo signaling component upstream of
Hpo/MST and Merlin.
38,39 This modularity in the Hippo
pathway might intend that this pathway is regulated by WW
domain-containing proteins at different levels in the pathway,
from the mediators down to the core components and
effectors.
WW Domain Proteins Regulate Members of the Hippo
Pathway
WW domains of kibra regulate Hippo pathway
proteins. Recently, different reports have described
growing evidence of a number of proteins that regulate the
core components of the Hippo pathway. Some of these
proteins can be broadly termed upstream Hippo pathway
regulators and include proteins that signal via the atypical
cadherin, Fat, which functions as a transmembrane receptor
for the Hippo pathway.
32 Additionally, the Kibra–Expanded–
Merlin complex links the apical membrane to the core of the
pathway proteins and the apicobasal polarity proteins.
32
These upstream regulators make different physical
interactions with the pathway to manipulate its functions.
One example of these interactions is the WW domain–PPxY
motif interaction induced by Kibra. Recently, it has been
shown that different null mutants of the Kibra gene are
associated with increased cell number leading to tissue
overgrowth. On the other hand, Kibra overexpressing clones
contain fewer cells than control clones associated with
induced apoptosis.
40 Kibra functions primarily upstream
of Mer and contributes to Mer-independent regulation of
Yki activity. This effect on Mer seemed to be mediated
by physical interaction of the two proteins. This interaction
was found to be independent of the WW domains of Kibra.
40
On the other hand Ling Xiao et al.
41 showed that the Kibra
WW domains are essential for Kibra–LATS interaction
and regulation of LATS1/2 functions in the context of the
mammalian Hippo pathway. Upon its expression, Kibra
activates LATS1/2 as revealed by its increased phos-
phorylation, leading to increased phosphorylation of the
ultimate effector of the pathway, YAP.
41 Not only was Kibra
shown to enhance LATS function but it was also shown to be
responsible for increased LATS2 protein levels. Kibra-LATS2
association increases LATS2 half-life, at least in part, by
inhibiting LATS2 ubiquitination and its proteasomal
degradation.
41 Implication of this functional interaction on
tumorigenesis in vivo is still to be determined.
WW domains of ITCH regulates LATS1 stability. Re-
cently, two reports identiﬁed the E3 ligase responsible for the
proteasomal degradation of LATS1. The ﬁrst, coming from
our lab, identiﬁed ITCH as a WW domain-containing protein
that regulates the stability of LATS1 using WW domain
arrays.
42 These ﬁndings were conﬁrmed later by another
group that utilized SILAC (Stable Isotope Labeling with
Amino Acids in cell culture).
43 Both articles came to the same
conclusion, identifying LATS1 as a target of the E3 ligase
ITCH (Figure 1). In our work, we demonstrated that ITCH,
mostly via its ﬁrst WW domain, interacts with the PPxY motifs
of LATS1 and enhances its ubiqitination and proteasomal
degradation.
42 Of note, ITCH interaction with LATS1 was
increased upon activation of the Hippo pathway either
by MST2 overexpression or by high-cell density culture.
This interaction was associated with enhanced degradation
of LATS1 and suggest that ITCH might speciﬁcally target
the activated form of LATS1.
42 Expression of a kinase-dead
mutant of MST2 (MSTD-KD), which is incapable of phos-
phorylating and activating LATS1, indeed rescued, at least in
part, ITCH-mediated LATS1 degradation (Unpublished
data, Salah and Aqeilan). Whether ITCH expression and/or
function is affected by LATS kinases is still an open question.
Collectively, this may suggest that ITCH might function
as a ﬁne-tuning regulator of the Hippo pathway under
physiological conditions.
ITCH-mediatedLATS1degradationisalsoaccompaniedby
reduced YAP phosphorylation on Ser127, mild YAP accumu-
lation in the nucleus and increased co-activation function of
TEAD-responsive genes.
42 As YAP phosphorylation has
been shown to trigger its degradation by SCF-(bTRCP) E3
ubiquitinligase,ourresultsmaysuggestthatITCHexpression
might signal for YAP stabilization and TEAD co-activation.
42
The ﬁndings by Salah et al.
42 further demonstrated that
LATS1 degradation by ITCH enhances EMT in HeLa and
MCF10A cells, phenocopying overexpression of YAP.
1,3
Increased levels of YAP-related EMT genes, including CTGF
and ﬁbronectin, and increased cellular migration and invasion
are hallmarks of ITCH overexpression. Not only did the cells
show more EMT phenotypes but also ITCH-manipulated cells
are more tumorigenic both in vitro and in vivo. The ﬁndings of
Ho et al.
43 also conﬁrmed that ITCH negatively regulates
LATS1 level and function as related to cell proliferation and
apoptosis in the same way as demonstrated earlier.
42
Because ITCH, as an E3 ligase, targets many substrates,
44,45
it is possible to speculate that the phenotypes observed after
ITCH overexpression are related to the regulation of the
different targets in a given context. Nevertheless, these
phenotypeswererescued,atleastinpart,inoursettingswhen
manipulating LATS1 expression, suggesting that LATS1 is a
criticaltargetofITCH-mediatedtumorgrowthandprogression
by regulating the Hippo pathway.
As different WW domain proteins may share common
targets, it is likely to assume that changing the level, stability
or subcellular localization of one WW protein would alter the
function and outcome of WW domain targets, depending on
the cellular context or the expression of the different
proteins.
17,30 For example, p73 is a common ligand for ITCH
and YAP. On one hand, ITCH degrades p73,
44 while on the
other hand it leads to enhanced YAP translocation to the
nucleus to promote TEAD-dependent transcription.
3 In addi-
tion, YAP is an important co-factor for p73-dependent
transcriptional activity and exerts a tumor suppressor role in
this context.
45 Therefore, ITCH overexpression might serve
as a molecular switch between opposing YAP functions.
Whether YAP relocates between p73/YAP targets and TEAD/
YAP targets in response to ITCH is to be determined in future
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targeted manipulation of WW domain proteins or their
interacting partners in the Hippo pathway would tilt the
outcome of organ size and/or tumorigenicity. As ITCH
behaves as a proto-oncogene, it might also contribute to the
observed downregulation of LATS1 levels in cancer, and
possibly other components of the Hippo tumor suppressor
pathway. In summary, these ﬁndings suggest that novel WW
domains could regulate the core components of the Hippo
pathway thereby affecting tumorigenesis and, perhaps,
organ growth.
PPxY-containing proteins regulate effectors of the
Hippo pathway. Another level where WW domains appear
to regulate the Hippo pathway is on the level of the effectors,
YAP and TAZ. Indeed, LATS proteins, via their PPxY motifs,
have been shown to bind to WW domains of YAP leading to
YAP phosphorylation, sequestration in the cytoplasm and
inactivation.
33,34,46 This leads to reduce YAP-induced EMT
phenotypes and is associated with reduced tumor-
igenicity.
1,34 In fact, it was shown that the WW domain of
YAP has a critical role in inducing a subset of YAP target
genes independent of, or in cooperation with, TEAD.
37 In
addition, mutagenesis of the WW domains diminishes the
ability of YAP to stimulate cell proliferation and oncogenic
transformation.
37 In support of this notion, two recent papers
showed that WW domain-mediated interaction with WBP2
is important for the phenotypes induced by both Yki
47
and TAZ.
48 In the ﬁrst work, Zhang et al.
47 reported that
Yki, via its WW domain, binds to the PPxY motifs of Wbp2.
Importantly this interaction leads to increased Yki
transcriptional co-activation function and is associated with
Yki-driven tissue overgrowth. Knockdown of Wbp2
expression by RNAi in a wts-deﬁcient background reversed
the lethal overgrowth phenotypes in wts null organisms,
suggesting that Yki function is mediated by Wbp2.
47 In
mammalian cells, TAZ’s WW domains’ interaction with PPxY
motifs of WBP2 suggested an indispensable role of WBP2 in
TAZ transforming ability.
48 Although knockdown of WBP2
suppressed TAZ-driven transformation, its overexpression
enhanced this transformation.
48
Recently, the PPxY-containing Angiomotin (AMOT)-like
proteins 1 and 2 (AMOTL1/AMOTL2) were identiﬁed as
regulators of the downstream effectors of the Hippo pathway,
YAP and TAZ.
49–51 Three articles highlight the signiﬁcance of
thisinteractionandshedlightontheroleofAMOTcelljunction
proteins in regulating YAP and TAZ function.
49–51 These
proteins were found to speciﬁcally interact with YAP in a WW
domain-PPxY motif-dependent manner. This interaction was
found to be sufﬁcient to sequester YAP and TAZ in the
cytoplasm, independent of their phosphorylation status.
Speciﬁcally, AMOT expression leads to YAP localization at
the tight junction and cell membrane, preventing YAP nuclear
translocation.
51 Moreover, it was shown that knockdown of
AMOTL2 phenocopies YAP-induced EMT in MCF10A cells.
51
Considering this scenario, loss of tight junction-localized YAP
and TAZ increased their nuclear localization and was
accompanied by induction of YAP/TAZ target gene expres-
sion, and most importantly, transformation and loss of cell
contact inhibition. Furthermore, AMOTL2 knockdown-depen-
dentphenotypeswereblockedbysimultaneousknockdownof
YAP and TAZ, demonstrating that the AMOT family proteins
are new components of the Hippo pathway with tumor-
suppressing potential, indicating a new mode of YAP and
TAZ regulation.
51
In a different manner, WW domain-PPxY motif interaction
was involved in the regulation of the downstream effectors
of the Hippo pathway by involving more than two proteins.
For example, ASPP2 was shown to stimulate TAZ depho-
sphorylation, partly by promoting the interaction between TAZ
and PP1; this function of ASPP2 requires the TAZ WW
domain. ASPP2–TAZ interaction promotes TAZ nuclear
localization and TAZ target gene expression.
52 In another
example, it was shown that ASPP1 was able to inhibit
YAP/TAZ interaction with LATS1, leading to enhanced
nuclear accumulation of YAP/TAZ and YAP/TAZ-dependent
transcriptional regulation. This results in YAP/TAZ activation
and thus inhibits apoptosis, in part, through the downregula-
tion of Bim expression, leading to resistance to anoikis and
enhanced cell migration.
53
Concluding Remarks and Future Directions
The unique feature of the Hippo pathway over other signaling
pathways is its high modularity represented by the great
prevalence of WW–PPxY interactions, which might strongly
suggest that other WW domain and PPxY motif-containing
proteins regulate,or are part of, the Hippo pathway. The study
of WW domains and Hippo pathway in recent years further
highlightedimportantaspectsofWWdomainproteinsignaling
including dimerization capability, regulation of WW domain-
PRM interaction and networking (reviewed in Sudol
5). WW
domains are present in a wide variety of cellular proteins
includingE3ligases,co-activators,co-repressorsandadapter
proteins that could potentially regulate members of the Hippo
pathway. Taking into consideration the important role of this
pathway in tissue growth and homeostasis, further efforts
should be invested in identifying new regulators and compo-
nents of this pathway. The use of GFP-expressing tumor cells
in fresh tissue or live animals shall facilitate better chara-
cterization of the Hippo pathway proteins and their role, both
in vitro and in vivo, in tumor initiation and progression.
54–57
Expansion of this information may aid in developing new
therapeutic strategies based on the WW domain interactions
in this pathway. In fact, the design of inhibitors or activators of
WW domain signaling complexes in the Hippo pathway could
be facilitated by the considerable data available on the WW
domain structure, the mechanism of interaction with its rigid
ligands, and the complexes it forms.
58 Owing to the fact that
the WW domain and its ligands’ core motifs are relatively
short, it might be possible to use small molecules that function
as activators or inhibitors for the Hippo pathway signaling
proteins;thatis,smallchemicals/peptidesthatinhibitYAPand
TAZ oncogenic function. However, before thinking about
therapeutic strategies based on WW domain interactions,
furtheranalysisoftheWWdomain-mediatedcomplexesinthe
Hippo pathway must be elucidated to better design novel
therapeutic strategies for malfunctions that involve the WW
domain.
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